3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
14
INDUSTRY
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
3
CNS
2
Conditions
Disease
2
Brain Neoplasms
2
Interventions
Temozolomide
123
Radiotherapy
47
Bevacizumab
46
Lomustine
25
Radiation
20
Nivolumab
17
Irinotecan
16
Carboplatin
16
Cyclophosphamide
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
pembrolizumab
11
dabrafenib
10
Trastuzumab
10
Surgical Procedures, Operative
10
Capecitabine
10
paclitaxel-Angiopep-2 conjugate
8
TIC10 compound
8
Paclitaxel
8
Gemcitabine
8
Carmustine
8
trametinib
7
Topotecan
7
IL13-PE38
7
Everolimus
7
Drug Therapy
7
Aminolevulinic Acid
7
AZD 6244
7
3-Iodobenzylguanidine
7
fludarabine
6
enzastaurin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
fluciclovine F-18
×
CNS
×
Clear all
NCT04410133
2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3
Completed
151 enrolled
29 charts
NCT04410367
2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2
Completed
23 enrolled
10 charts